New diagnostic criteria for multiple sclerosis integrating magnetic resonance image
assessment with clinical and other paraclinical methods were introduced in 2001. The “McDonald …

… Wolinsky has received compensation for service on steering committees or data monitoring
boards for Novartis Pharmaceuticals, Sanofi, and Teva Pharmaceuticals; reimbursement for …

Article abstract MRI is very sensitive in showing MS lesions throughout the CNS. Using MRI
for diagnostic purposes, however useful, is a complex issue because of limited specificity of …

New evidence and consensus has led to further revision of the McDonald Criteria for diagnosis
of multiple sclerosis. The use of imaging for demonstration of dissemination of central …

The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple
sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in …

Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer
acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (…

we studied copolymer 1 (Copaxone) in a multicenter (11-university) phase III trial of patients
with relapsing-remitting multiple sclerosis (MS). Two hundred fifty-one patients were …

Background An evolving understanding of the immunopathogenesis of multiple sclerosis
suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a humanized
monoclonal antibody that selectively depletes CD20+ B cells. Methods In two identical …

Background Teriflunomide is a new oral disease-modifying therapy for relapsing forms of
multiple sclerosis. Methods We concluded a randomized trial involving 1088 patients with …